NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded
Will Seek EUA Shortly
Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.
You may also be interested in...
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.